Title: Current and emerging medications for the management of obesity in adults
Abstract: Medical Journal of AustraliaEarly View Letter Current and emerging medications for the management of obesity in adults Joshua M Inglis, Corresponding Author Joshua M Inglis [email protected] Flinders Medical Centre, Adelaide, SA Flinders University, Adelaide, SA University of Adelaide, Adelaide, SA[email protected]Search for more papers by this authorGanessan Kichenadasse, Ganessan Kichenadasse Flinders Medical Centre, Adelaide, SA Flinders University, Adelaide, SASearch for more papers by this authorArduino A Mangoni, Arduino A Mangoni Flinders Medical Centre, Adelaide, SA Flinders University, Adelaide, SASearch for more papers by this author Joshua M Inglis, Corresponding Author Joshua M Inglis [email protected] Flinders Medical Centre, Adelaide, SA Flinders University, Adelaide, SA University of Adelaide, Adelaide, SA[email protected]Search for more papers by this authorGanessan Kichenadasse, Ganessan Kichenadasse Flinders Medical Centre, Adelaide, SA Flinders University, Adelaide, SASearch for more papers by this authorArduino A Mangoni, Arduino A Mangoni Flinders Medical Centre, Adelaide, SA Flinders University, Adelaide, SASearch for more papers by this author First published: 04 July 2023 https://doi.org/10.5694/mja2.52028Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Walmsley R, Sumithran P. Current and emerging medications for the management of obesity in adults. Med J Aust 2023; 218: 276-283. https://www.mja.com.au/journal/2023/218/6/current-and-emerging-medications-management-obesity-adults#:~:text=Five%20agents%20are%20currently%20approved,receptor%20agonists%20liraglutide%20and%20semaglutide 2Smits MM, Van Raalte DH. Safety of semaglutide. Front Endocrinol (Lausanne) 2021; 12: 645563. 3Abd El Aziz M, Cahyadi O, Meier JJ, et al. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diabetes Obes Metab 2020; 22: 699-704. 4Bezin J, Gouverneur A, Pénichon M, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care 2023; 46: 384-390. 5Thompson CA, Stürmer T. Putting GLP-1 RAs and thyroid cancer in context: additional evidence and remaining doubts. Diabetes Care 2022; 46: 249-251. Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation
Publication Year: 2023
Publication Date: 2023-07-04
Language: en
Type: letter
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 1
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot